📋 Product Overview Table

🌐 Specification	🧾 Details
💊 Active Ingredient	Liraglutide
🧪 Strength	6 mg/mL
🏭 Manufacturer	Novo Nordisk India
💉 Form	Subcutaneous Injection (Pre-filled Pen)
📦 Packaging	3 mL in 1 disposable pen
🩺 Indication	Type 2 Diabetes Mellitus; Chronic Weight Management (off-label)
🇺🇸 US Brand	Victoza
⏱️ Delivery Time	6 to 15 days

🧬 Introduction – Victoza 6mg/mL (Liraglutide) by Novo Nordisk India

Victoza (Liraglutide 6mg/mL) by Novo Nordisk India is a globally recognized GLP-1 receptor agonist used to manage Type 2 diabetes and support weight loss in certain patients. Delivered through a pre-filled pen, this once-daily injectable mimics human incretin hormones, enhancing insulin secretion, reducing appetite, and delaying gastric emptying.

With strong cardiovascular benefits and a proven track record in long-term glucose control, Victoza is trusted worldwide and recommended by many leading diabetes associations. This Indian version maintains international quality standards and is widely exported to patients across the globe.

🎥 Video Overview – Victoza Explained

📺 “How Victoza Works: GLP-1 Therapy for Diabetes and Obesity“

🎬 Video Placeholder – A clear explanation of Liraglutide’s mechanism, injection guidance, and patient benefits.

Inject subcutaneously in the abdomen, thigh, or upper arm at the same time each day. Do not share pens.

🩺 Indications & Medical Benefits

Improves blood glucose control in adults with Type 2 diabetes
Supports weight loss and appetite regulation (off-label)
Delays need for insulin initiation in early diabetes
May reduce risk of major cardiovascular events in high-risk patients

💡 Dosage Recommendations

🕒 Treatment Stage	💊 Dosage Guidelines
Initiation Phase	Start with 0.6 mg daily for 7 days
Maintenance Phase	Increase to 1.2 mg/day; may escalate to 1.8 mg/day as needed
Administration Route	Subcutaneous injection (once daily)

Avoid combining with insulin in the same syringe. Monitor blood sugar regularly.

⚠️ Side Effects & Safety Notes

💥 Common Reactions	❗ Serious Risks
Nausea, diarrhea, dizziness	Acute pancreatitis, renal dysfunction
Injection site reactions	Thyroid C-cell tumors (seen in rodent studies)
Appetite suppression	Gallbladder disease

Not recommended for: Patients with a history of medullary thyroid carcinoma or MEN 2 syndrome.

🧃 Storage Instructions

Store unused pens in refrigerator (2°C to 8°C)
After first use, may be stored below 30°C for up to 30 days
Do not freeze or expose to direct light

🌍 Global Availability & Ordering Info

🌎 Region	📦 Import Policy	📋 Prescription Requirement
🇺🇸 USA	FDA allows personal import (Rx required)	Yes
🇬🇧 UK	Permitted via MHRA guidelines	Yes
🇦🇺 Australia	Allowed under TGA personal import scheme	Yes

🔗 Related Products (Internal Links)

💊 Medicine	🏭 Manufacturer	📖 Description
ERLY 6mg/mL	Eris Lifesciences	Affordable GLP-1 pen injection for diabetes
Lirafit Pen	Glenmark / Novo Nordisk	Indian alternative to Victoza, similar action profile
Ozempic 1mg	Novo Nordisk	Weekly injectable Semaglutide formulation
Rybelsus 14mg	Novo Nordisk India	Oral Semaglutide for Type 2 diabetes
Trulicity 1.5mg	Eli Lilly	Long-acting GLP-1 agonist, once weekly

📚 References & Medical Sources

FDA Victoza Prescribing Info
Novo Nordisk Official Site
NHS – GLP-1 Therapy Guidelines
PubMed – Victoza Clinical Data

🩺 Doctor Insight – Dr. Sandeep R. Kulkarni, MD (Endocrinology)

“Victoza remains one of the most effective GLP-1 options for diabetes and metabolic control. Its use is backed by solid data on cardiovascular safety and patient outcomes. Novo Nordisk India delivers high-quality formulations that meet global demand.”

⚠️ Disclaimer

This content is intended for informational purposes only. Victoza (Liraglutide) is a prescription-only medication. Always consult a licensed physician before starting treatment.